- In March 2025, Johnson & Johnson MedTech announced the launch of its DUALTO Energy System, a surgical solution that combines multiple energy modalities (monopolar, bipolar, ultrasonic, and advanced bipolar) into a single, integrated platform. This system is designed for both open and minimally invasive surgery and can be paired with service solutions and digital fleet management software, aiming to simplify surgical energy delivery and enhance operating room efficiencies
- In February 2025, Ebble Group, including Tantec-UK, highlighted significant expansion and new equipment installations in early 2025, following a move to a larger site in 2023. This includes investment in new factory equipment such as a large robot cell with atmospheric plasma and SpotTEC treatment systems, aimed at improving their product portfolio and services, which include applications relevant to medical device surface treatment
- In January 2025, Advanced Energy Introduces NCF660 CF-Rated Medical Power Supplies. Advanced Energy Industries, Inc. expanded its family of convection-cooled, cardiac floating (CF)-rated medical power supplies with the NCF660. These power supplies are designed for critical medical devices that have direct cardiac or bloodstream contact, aiming to simplify the design and speed time-to-market for applications such as surgical generators, cardiac assist devices, and RF ablation
- In February 2024, Butterfly Network announced the commercial launch of its third-generation handheld point-of-care ultrasound (POCUS) system, Butterfly iQ3, in the United States. This device is built on new Ultrasound-on-Chip technology with enhanced frame rates, frequency, and new 3D imaging capabilities, designed to improve image resolution and diagnostic accuracy at the point of care
- In November 2023, Medtronic received U.S. FDA approval for its Symplicity Spyral multi-electrode renal denervation catheter. This innovative, minimally invasive procedure delivers radiofrequency energy to nerves near the kidneys to help reduce blood pressure in patients with hypertension that is not adequately controlled by lifestyle modifications and medications
